+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
All Genders
ID06869239

Study of PD-L1 Inhibitor Treatment After Chemoradiotherapy in Adults With Limited-Stage Small Cell Lung Cancer Using Liquid Biopsy to Predict Response

Led by Peking University Cancer Hospital & Institute · Updated on 2025-03-11

65

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of immunotherapy using PD-L1 inhibitors as maintenance treatment after high-dose hyperfractionated simultaneous integrated boost radiotherapy combined with chemotherapy in patients with limited-stage small cell lung cancer LS-SCLC. This prospective observational study also uses liquid biopsy technology to identify biomarkers that could predict how well patients respond to PD-L1 inhibitors following chemoradiotherapy. Participants receive four courses of intravenous chemotherapy with cisplatin or carboplatin plus etoposide every three weeks, alongside high-dose twice-daily thoracic radiotherapy during the first three cycles. For those achieving partial or complete response, prophylactic cranial irradiation is given 3 to 4 weeks after chemoradiotherapy. Maintenance therapy with PD-L1 inhibitors such as Durvalumab, Atezolizumab, Sugemalimab, or Adebrelimab is administered until disease progression, death, intolerable toxicity, or up to two years. Throughout the study, participants will be monitored for progression-free survival, overall survival, response rates, disease control, and adverse events for up to three years. Evaluations include clinical assessments, imaging, laboratory tests, and liquid biopsies to track biomarkers. Safety monitoring continues for 30 days after treatment ends, and participants are followed for long-term outcomes to better understand treatment effects and potential risks.

CONDITIONS

Brief Title

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

Research Team

A

Anhui Shi

J

Jiayi Yu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here